Product Description: Evatanepag (CP-533536) is a non-prostanoid, potent and selective EP2 receptor agonist. Evatanepag can induce local bone formation in vivo. Evatanepag can be used in the research of fractures, bone defects, asthma[1][2].
Applications: COVID-19-immunoregulation
Formula: C25H28N2O5S
References: [1]Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8./[2]Judith Plaza, et al. In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity. Allergy Asthma Immunol Res. 2020 Jul;12(4):712-728. /[3]V M Paralkar, et al. An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. Proc Natl Acad Sci U S A. 2003 May 27;100(11):6736-40.
CAS Number: 223488-57-1
Molecular Weight: 468.57
Compound Purity: 99.78
Research Area: Endocrinology; Inflammation/Immunology; Cardiovascular Disease
Solubility: DMSO : ≥ 32 mg/mL
Target: Prostaglandin Receptor
English
Deutsch
